Business
Equillium to Present at the Stifel Healthcare Conference
LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to
About this update from Equillium, Inc.
[{"type":"text","content":" LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Stifel Healthcare Conference taking place in New York on November 18 & 19, 2024.\n\n\nManagement will provide an overview of the Company’s clinical programs, currently focused on the Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD) and the Phase 2 study of itolizumab in ulcerative colitis. Management will be available for one-on-one meetings during the conference.\n\n\n\n\nConference:\n\n\n\n\n\n\nStifel Healthcare Conference\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nLocation:\n\n\n\n\n\n\nLotte New York Palace Hotel\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nDates:\n\n\n\n\n\n\nMonday, November 18 & Tuesday, November 19\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nPresentation:\n\n\n\n\n\n\nTuesday, November 19 at 9:40 am Pacific Time | 12:40 pm Eastern Time\n\n\n\n\n\n\n \n\n\n\n\n\n\n\nWebcast access for the conference will be available on the Events & Presentations page under the Investor Relations tab on the Company’s website. An archived replay of both presentations will be available for 90 days.\n\n\nAbout Equillium\n\n\nEquillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of the following novel first-in-class immunomodulatory assets and product platform targeting immuno-inflammatory pathways. Itolizumab: a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells that drive a number of immuno-inflammatory diseases; currently under evaluation in a Phase 3 clinical study of patients with acute graft-versus-host disease (aGVHD) and announced positive data from a Phase 1b clinical study of patients with lupus/lupus nephritis in April 2024. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited, who also provides commercial manufacturing for the product. EQ101: a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15; recently announ...